EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis

Vereinfachte perioperative Serplulimab- und Chemotherapie bei resektablem squamösem NSCLC: Phase-II-Studie mit Biomarkeranalyse

Fangqiu Fu, Haoxuan Wu, Chaoqiang Deng, Haiqing Chen, Qingyuan Huang, Chongze Yuan, Xusheng Ding, Ting Ye, Yaodong Zhou, Sufeng Chen, Yihua Sun, Yawei Zhang und 8 weitere

Journal for ImmunoTherapy of Cancer · 2026-05 · 14 (5) · e014437

DOI: 10.1136/jitc-2025-014437 ↗

Auf einen Blick

In einer einarmigen Phase-II-Studie bei resektablem Stadium II-IIIA sq-NSCLC zeigte ein perioperatives Regime mit Serplulimab und Taxan/Carboplatin hohe MPR- und pCR-Raten.

Fragestellung

Wie machbar und wirksam ist ein vierzykliges perioperatives Regime aus Serplulimab plus Taxan/Carboplatin bei resektablem Stadium II-IIIA sq-NSCLC?

Methode

Einarmige, investigator-initiiere Phase-II-Studie; neoadjuvante Serplulimab-plus-Taxan/Carboplatin-Gabe, OP, dann adjuvante Behandlung; primärer Endpunkt MPR.

Ergebnisse

30 Patient:innen wurden eingeschlossen, 29 operiert. R0-Resektion bei 96,55 % (28/29); MPR 76,67 %, pCR 50,00 %. ORR 73,33 % (95 %-KI 54,11 %–87,72 %).

Einschränkungen

Langzeitdaten zu EFS und OS noch nicht ausgereift.

Schlussfolgerung der Autor:innen

Ein vierzyklisches perioperatives Regime mit Serplulimab plus Taxan/Carboplatin zeigte vielversprechende MPR- und pCR-Raten bei akzeptablem Sicherheitsprofil; Phase-III-Studien sind nötig.

Kernaussagen

  • MPR 76,67 % und pCR 50,00 %
  • ORR 73,33 % (95 %-KI 54,11 %–87,72 %)
  • ctDNA-Clearance korrelierte mit pCR (p=0,004)

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 11.05.2026. Verfasst von Fangqiu Fu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Medical Research Special Project for Shanghai Science and Technology Innovation Action Plan, Shanghai Henlius Biotech, the National Natural Science Foundation of People’s Republic of China.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Squamous non-small cell lung cancer (sq-NSCLC) is a distinct subtype of NSCLC. This exploratory, phase II study investigated the feasibility and efficacy of a four-cycle perioperative regimen combining serplulimab with a taxane (paclitaxel or nab-paclitaxel) and carboplatin in patients with resectable stage II-IIIA sq-NSCLC.

Methods

This investigator-initiated, single-arm, phase II exploratory trial ( NCT05775796 ) enrolled patients with histologically confirmed, resectable clinical stage II-IIIA squamous NSCLC. Patients received two to three cycles of neoadjuvant serplulimab plus taxane-carboplatin, followed by curative-intent surgery and one to two cycles of adjuvant treatment. The primary endpoint was major pathological response (MPR). Secondary endpoints included pathological complete response (pCR), R0 resection rate, overall response rate (ORR), safety, event-free survival (EFS), and overall survival (OS).

Results

A total of 30 patients without actionable driver alterations were enrolled and 29 underwent surgery. The median age was 65 years, and most were male smokers (n=28, 93.33%). Surgery was performed in 29 patients, and R0 resection was achieved in 96.55% (28/29) of the surgically resected patients. Among all enrolled patients, MPR and pCR rates were 76.67% and 50.00%, respectively. Based on radiological assessments during the neoadjuvant phase, the ORR was 73.33% (95% CI 54.11% to 87.72%). Grade ≥3 treatment-related adverse events were predominantly hematologic and were generally manageable. Long-term EFS and OS data are not yet mature. Additionally, exploratory minimal residual disease analysis using circulating tumor DNA (ctDNA) in 27 patients showed a strong correlation between ctDNA clearance and pCR (p=0.004), suggesting ctDNA as a promising biomarker for immunochemotherapy response.

Conclusions

A four-cycle perioperative regimen of serplulimab combined with taxane-carboplatin demonstrated promising MPR and pCR rates with an acceptable safety profile in patients with resectable sq-NSCLC. Long-term follow-up and future phase III trials are warranted to confirm these exploratory findings. Trial registration number NCT05775796 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsAgedFemaleHumansMaleMiddle AgedAlbuminsCarboplatinNeoadjuvant TherapyPaclitaxelPathologic Complete ResponseAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Immune Checkpoint InhibitorLung CancerMinimal residual disease - MRDNeoadjuvant

Substanzen

130-nm albumin-bound paclitaxelAlbuminsBiomarkers, TumorCarboplatinPaclitaxelserplulimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Institute of Thoracic Oncology, Fudan University, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Burning Rock Biotech, Guangzhou, Guangdong, China.

Förderung

  • the Medical Research Special Project for Shanghai Science and Technology Innovation Action Plan
  • Shanghai Henlius Biotech
  • the National Natural Science Foundation of People’s Republic of China
  • Burning Rock Biotech
  • the Clinical Research Special Project of Shanghai Municipal Health Commission
  • the National Key R&D Program of China

Zitieren

APA

Fu, F., Wu, H., Deng, C., Chen, H., Huang, Q., Yuan, C., Ding, X., Ye, T., Zhou, Y., Chen, S., Sun, Y., Zhang, Y., Xiang, J., Wang, S., Li, Y., Li, B., Lu, Y., Zhang, Y., Hu, H., & Chen, H. (2026). Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis. Journal for ImmunoTherapy of Cancer, 14(5), e014437. https://doi.org/10.1136/jitc-2025-014437

Vancouver

Fu F, Wu H, Deng C, Chen H, Huang Q, Yuan C, et al. Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis. Journal for ImmunoTherapy of Cancer. 2026;14(5):e014437. doi:10.1136/jitc-2025-014437

BibTeX
@article{Fu2026,
  author = {Fu, Fangqiu and Wu, Haoxuan and Deng, Chaoqiang and Chen, Haiqing and Huang, Qingyuan and Yuan, Chongze and Ding, Xusheng and Ye, Ting and Zhou, Yaodong and Chen, Sufeng and Sun, Yihua and Zhang, Yawei and Xiang, Jiaqing and Wang, Shengping and Li, Yuan and Li, Bing and Lu, Yi and Zhang, Yang and Hu, Hong and Chen, Haiquan},
  title = {Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {5},
  pages = {e014437},
  doi = {10.1136/jitc-2025-014437}
}
Kostenlos starten →